ALK and non-small cell lung carcinoma: To examine whether brigatinib exhibits a growth inhibition effect in ALK-negative cancer cells, ALK-positive NSCLC cell line (H3122 and H2228) and various ALK-negative cancer cells lines (A549, Hep3B, Du145, HCT116) were treated with brigatinib.